Maxim Group downgraded shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) from a buy rating to a hold rating in a research report report published on Tuesday morning, MarketBeat Ratings reports.

Separately, ValuEngine raised ContraVir Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, February 2nd.

Shares of ContraVir Pharmaceuticals (CTRV) opened at $0.26 on Tuesday. ContraVir Pharmaceuticals has a 1 year low of $0.23 and a 1 year high of $1.96.

A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Vanguard Group Inc. lifted its stake in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,414,475 shares of the biopharmaceutical company’s stock after buying an additional 366,192 shares during the period. Vanguard Group Inc. owned approximately 3.79% of ContraVir Pharmaceuticals worth $1,400,000 as of its most recent SEC filing. Institutional investors own 6.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “ContraVir Pharmaceuticals (CTRV) Rating Lowered to Hold at Maxim Group” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2018/02/14/contravir-pharmaceuticals-ctrv-rating-lowered-to-hold-at-maxim-group.html.

About ContraVir Pharmaceuticals

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.